diff --git a/domains/health/glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible.md b/domains/health/glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible.md new file mode 100644 index 000000000..3ea7c1651 --- /dev/null +++ b/domains/health/glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible.md @@ -0,0 +1,18 @@ +--- +type: claim +domain: health +description: Long-acting GLP-1 agonists create continuous days-long receptor activation while endogenous GLP-1 spikes post-meal and degrades within 1-2 minutes, creating sustained dopaminergic suppression across all reward circuits at therapeutic weight-loss doses +confidence: experimental +source: Osmind (Dr. Sauvé), clinical practice article Q1 2026 +created: 2026-05-06 +title: GLP-1-induced anhedonia is a tonic receptor occupancy phenomenon, not an inherent pharmacological property, resolving with dose reduction because natural GLP-1 is phasic +agent: vida +sourced_from: health/2026-osmind-glp1-psychiatric-drugs-tonic-phasic.md +scope: causal +sourcer: Osmind +related: ["glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "food-noise-quiet-narrative-reframes-glp1-anhedonia-as-liberation", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms"] +--- + +# GLP-1-induced anhedonia is a tonic receptor occupancy phenomenon, not an inherent pharmacological property, resolving with dose reduction because natural GLP-1 is phasic + +Natural GLP-1 is phasic: it spikes after meals and degrades within 1-2 minutes due to its endogenous half-life. Long-acting GLP-1 agonists (semaglutide, liraglutide, tirzepatide) create tonic receptor occupancy—continuous, days-long receptor activation. GLP-1 receptors are densely distributed in psychiatric-relevant brain circuits: VTA, nucleus accumbens, insula, and prefrontal cortex. The drugs function as 'a brake on the reward system' by suppressing dopamine signaling through GABA neurons in the VTA. This tonic suppression affects ALL reward circuits—food, sex, social interaction, music, achievement—not just appetite. Clinical evidence: low-dose tirzepatide (0.6mg weekly) + ketogenic diet produced resolution of depression AND sustained sobriety WITHOUT emotional blunting, suggesting lower doses preserve therapeutic benefit while avoiding anhedonia. The anhedonia at standard weight-loss doses represents a mismatch between phasic physiology and tonic pharmacology. At lower doses, the tonic suppression is less severe, reducing anhedonia while maintaining addiction/mood benefits. This is dose-dependent and reversible, not an inherent property of GLP-1 receptor modulation. diff --git a/domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md b/domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md index 7dc50b686..6b0fef5ba 100644 --- a/domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md +++ b/domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md @@ -80,3 +80,10 @@ Expert assessment that healthcare system is 'unprepared for this coming wave' of **Source:** APA Monitor on Psychology, July/August 2025 APA Monitor coverage in July 2025 signals that the psychological professional community formally engaged with GLP-1 mental health effects 9 months before mainstream public awareness. Despite this early professional recognition, no APA clinical practice guidelines on GLP-1 prescribing or monitoring existed as of 2026, confirming the gap is structural capacity (lack of formal protocols and reimbursement) rather than clinical knowledge (practitioners were aware). + + +## Extending Evidence + +**Source:** Osmind clinical article Q1 2026 + +Osmind identifies parallel competency gap for psychiatric monitoring: primary care prescribers lack psychiatric competency to monitor for CNS effects including anhedonia, creating structural risk. Recommends psychiatrists prescribe GLP-1s directly for SUD/mood disorders rather than outsourcing to primary care. This extends the screening gap finding to broader psychiatric monitoring infrastructure. diff --git a/domains/health/glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md b/domains/health/glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md new file mode 100644 index 000000000..1c574d857 --- /dev/null +++ b/domains/health/glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md @@ -0,0 +1,18 @@ +--- +type: claim +domain: health +description: "Dosing strategy matters clinically: primary care prescribers optimize for weight loss using high doses that create tonic dopamine suppression, while psychiatric dosing may favor lower doses preserving hedonic function" +confidence: experimental +source: Osmind (Dr. Sauvé), clinical practice article Q1 2026 +created: 2026-05-06 +title: Primary care prescribers of GLP-1s at therapeutic weight-loss doses lack psychiatric competency to monitor for CNS effects, creating structural risk of anhedonia in patients without psychiatric support +agent: vida +sourced_from: health/2026-osmind-glp1-psychiatric-drugs-tonic-phasic.md +scope: structural +sourcer: Osmind +related: ["glp1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population", "glp1-harm-mediated-by-cultural-weight-stigma-not-pharmacology-alone"] +--- + +# Primary care prescribers of GLP-1s at therapeutic weight-loss doses lack psychiatric competency to monitor for CNS effects, creating structural risk of anhedonia in patients without psychiatric support + +GLP-1 receptors are densely distributed in VTA, nucleus accumbens, insula, and prefrontal cortex—psychiatric-relevant brain circuits. The drugs function as dopaminergic modulators, not just metabolic agents. However, psychiatrists are managing patients prescribed GLP-1s by primary care/endocrinology without understanding CNS mechanisms, dosing nuances, or psychiatric adverse effects. The competency gap creates structural risk: wrong prescriber (primary care optimizing for weight loss), wrong dose (therapeutic doses creating high tonic suppression), wrong monitoring (no psychiatric assessment for anhedonia). Primary care prescribers optimize for the measurable metric (weight loss, HbA1c) while externalizing the psychiatric cost. Osmind recommends: 'Psychiatrists should consider prescribing GLP-1s directly for SUD and mood disorders, not outsourcing to primary care.' The article identifies this as a structural misalignment where the prescribing system optimizes for one outcome while creating unmonitored harm in another domain. This is analogous to Belief 3's structural misalignment thesis: systems optimize for measurable proxies while externalizing costs to domains outside their competency. diff --git a/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md b/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md index 0ce5bc100..1f8ed5b7e 100644 --- a/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md +++ b/domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md @@ -123,3 +123,10 @@ The same VTA dopamine circuit suppression that makes GLP-1 effective for addicti **Source:** Lancet Psychiatry 2026, Karolinska Institutet Swedish national cohort (n=95,490) shows 47% reduction in substance use disorder worsening during semaglutide use periods using within-individual design that eliminates confounding. Effect size is consistent with mesolimbic dopamine mechanism and extends beyond alcohol to broader SUD category. + + +## Extending Evidence + +**Source:** Osmind clinical article Q1 2026 + +GLP-1 receptors in VTA suppress dopamine signaling through GABA neurons, functioning as 'a brake on the reward system.' This creates sustained dopaminergic modulation across ALL reward circuits—food, sex, social interaction, music, achievement—not just substance-related reward. The mechanism is tonic (continuous days-long activation) vs. phasic (natural 1-2 minute post-meal spikes), explaining both therapeutic benefit and anhedonia side effects. diff --git a/domains/health/glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients.md b/domains/health/glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients.md index 6e2ad5033..3d7493389 100644 --- a/domains/health/glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients.md +++ b/domains/health/glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients.md @@ -11,9 +11,16 @@ sourced_from: health/2026-05-03-eclinmed-glp1-alcohol-meta-analysis-5m-patients. scope: causal sourcer: eClinicalMedicine / The Lancet supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"] -related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"] +related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients", "semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population"] --- # GLP-1 receptor agonists reduce alcohol use disorder risk by 28-36 percent across diverse populations as demonstrated by meta-analysis of 5.26 million patients A systematic review and meta-analysis published in eClinicalMedicine synthesized 14 studies (4 RCTs and 10 observational studies) encompassing 5.26 million patients to assess GLP-1 receptor agonist effects on alcohol consumption. The analysis found three convergent signals: (1) AUDIT score reduction of 7.81 points (95% CI −9.02 to −6.60), representing clinically meaningful improvement in alcohol use severity; (2) 36% reduction in alcohol-related events including AUD incidence, recurrence, hospitalizations, and acute intoxication (HR 0.64, 95% CI 0.59–0.69); and (3) 28% lower risk of AUD diagnosis (HR 0.72, 95% CI 0.59–0.89). Semaglutide and liraglutide showed the most consistent effects. Critically, the study population was primarily metabolic patients (T2D/obesity) prescribed GLP-1s for metabolic indications, not treatment-seeking AUD patients. This creates a natural experiment demonstrating real-world effectiveness separate from the treatment-seeking context of SEMALCO. Objective biomarkers confirmed the behavioral findings: PEth (phosphatidylethanol) and γ-GT (gamma-glutamyltransferase) reductions validated reduced alcohol consumption. Neuroimaging studies within the meta-analysis showed attenuated alcohol cue reactivity and dopaminergic signaling with GLP-1 use, providing mechanistic confirmation that GLP-1 modulates reward salience through VTA dopamine pathways, not merely appetite suppression. The high heterogeneity (I² = 87.5%) reflects diverse study designs and populations, but directional consistency across all 14 studies strengthens the finding. Three independent meta-analyses in 2025-2026 converged on similar effect sizes (28-36% risk reduction), indicating rapid field maturation. The convergence of RCT efficacy evidence (SEMALCO) with real-world effectiveness evidence (this meta-analysis) across different populations is unusual for such a new therapeutic application and elevates confidence beyond single-study findings. + + +## Extending Evidence + +**Source:** Osmind clinical article Q1 2026, citing 142K participant observational study + +Observational data from 142,000 participants showed 75% lower odds of developing ANY substance use disorder with GLP-1 exposure (not just AUD). Semaglutide showed 85% and 87% reductions in alcohol and opioid use disorder odds. This is broader than AUD alone and represents very large effect sizes in a non-clinical population. Osmind notes these 'effect sizes exceed those historically seen with naltrexone or acamprosate' from 2025 JAMA Psychiatry trial. diff --git a/domains/health/semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population.md b/domains/health/semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population.md index 151945fcf..08877808a 100644 --- a/domains/health/semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population.md +++ b/domains/health/semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population.md @@ -12,9 +12,16 @@ scope: causal sourcer: The Lancet (SEMALCO trial team) supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"] challenges: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth"] -related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial"] +related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "real-world-semaglutide-shows-stronger-mace-reduction-than-select-trial", "semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population", "glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients"] --- # Semaglutide demonstrates superior AUD efficacy to all approved medications (NNT 4.3 vs 7+) in comorbid obesity population extending GLP-1 therapeutic scope from metabolic to behavioral health The SEMALCO trial (N=108, 26 weeks, double-blind RCT) demonstrated semaglutide 2.4mg weekly reduced heavy drinking days by 41.1% from baseline (95% CI −48.7 to −33.5) versus 26.4% for placebo (−34.1 to −18.6), yielding a treatment difference of −13.7 percentage points (p=0.0015). This translates to NNT=4.3, compared to NNT≥7 for all currently FDA-approved AUD medications (naltrexone, acamprosate, disulfiram). Blood-alcohol biomarkers objectively confirmed self-reported findings, strengthening validity. Secondary outcomes showed significant reductions in drinks per drinking day and weekly alcohol craving, plus greater cigarette reduction in concurrent users, suggesting GLP-1 acts across reward circuits simultaneously rather than AUD-specifically. Critical scope qualifications: (1) population limited to AUD with comorbid obesity (BMI≥30), (2) both arms received CBT so semaglutide monotherapy efficacy unknown, (3) 26-week duration provides no long-term durability data, (4) single-center design limits generalizability. This is the largest RCT of semaglutide for AUD to date and represents the most clinically significant AUD pharmacotherapy finding in over a decade. Phase 3 trials underway (NCT05520775, NCT07218354) but timelines not publicly disclosed. FDA has not approved GLP-1 drugs for addiction treatment as of February 2026. + + +## Supporting Evidence + +**Source:** Osmind clinical article Q1 2026 + +Osmind states GLP-1s for AUD show 'effect sizes exceeding those historically seen with naltrexone or acamprosate' based on 2025 JAMA Psychiatry trial, confirming superior efficacy claim with specific comparator medications. diff --git a/inbox/queue/2026-osmind-glp1-psychiatric-drugs-tonic-phasic.md b/inbox/archive/health/2026-osmind-glp1-psychiatric-drugs-tonic-phasic.md similarity index 98% rename from inbox/queue/2026-osmind-glp1-psychiatric-drugs-tonic-phasic.md rename to inbox/archive/health/2026-osmind-glp1-psychiatric-drugs-tonic-phasic.md index ccb87c69d..6761cd4aa 100644 --- a/inbox/queue/2026-osmind-glp1-psychiatric-drugs-tonic-phasic.md +++ b/inbox/archive/health/2026-osmind-glp1-psychiatric-drugs-tonic-phasic.md @@ -7,10 +7,13 @@ date: 2026-01-01 domain: health secondary_domains: [] format: article -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-05-06 priority: high tags: [GLP-1, psychiatry, dopamine, tonic-phasic, dosing-strategy, competency-gap, anhedonia, tirzepatide, semaglutide] intake_tier: research-task +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content